Indaptus Therapeutics Inc. (INDP) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While INDP currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.55) and Max Pain ($3.51) forces dealer call-delta covering toward $6.26.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Indaptus Therapeutics Inc. (INDP) advanced +0.30% to $3.34, trading at 48% of its 52-week range ($0.92 – $5.96). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
U.S. futures mixed; Netflix fell 6% after mixed Q3 results and weaker guidance. Alpha Teknova, Intuitive Surgical and others also declined premarket.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on INDP today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for INDP. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Indaptus Therapeutics Inc. (INDP) ranks #780 by composite RQD confidence (36/100, grade D-) and #446 by equity capitalization ($513.0M). Within this direct 5-issuer industry benchmark cohort, INDP leads on earnings valuation at N/A trailing P/E, while ARVN leads on capital efficiency and profitability with -32.1% ROIC and — gross margin. OCS currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with INDP at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INDP
ACTIVE
Indaptus Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | +0.30% | $513.0M | Benchmark Subject |
| DMAC DiaMedica Therapeutics Inc. | E | 34/100 | — | — | -35.0% | -3.05% | $513.4M | /dmac-vs-indp → |
| ARVN Arvinas Inc. | D- | 37/100 | — | — | -32.1% | +3.95% | $516.6M | /arvn-vs-indp → |
| OCS Oculis Holding AG | D+ | 58/100 | — | — | — | +3.26% | $507.5M | /ocs-vs-indp → |
| AQST Aquestive Therapeutics Inc. | E | 27/100 | — | 58.3% | -35.0% | -4.49% | $507.1M | /aqst-vs-indp → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Indaptus Therapeutics Inc. (INDP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$20.8M, operating cash flow of -$14.8M, and free cash flow of -$14.8M (-20.3% YoY). On the balance sheet, INDP closed FY2025 with $9.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$20.8M | -$14.8M | -$14.8M | $9.3M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$15.0M | -$12.3M | -$12.3M | $7.3M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$15.4M | -$13.4M | -$13.4M | — | — |
As of 2026-11-01, Indaptus Therapeutics Inc. (NASDAQ: INDP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $3.34 (+0.30% 1D, market cap $513.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, INDP ranks #780 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INDP carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DMAC (DiaMedica Therapeutics Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $513.4M) and ARVN (Arvinas Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -32.1%, cap $516.6M). Among the 5-stock peer group, INDP leads on earnings multiple (N/A) while ARVN leads on capital efficiency (-32.1% ROIC).
Per INDP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001857044), Indaptus Therapeutics Inc. generated $0 in revenue, -$20.8M in net income, and -$14.8M in free cash flow against $9.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
INDP last traded at $3.34 (+0.30% on volume of 84,379 shares), positioning the stock +30.98% above its 50-day simple moving average ($2.55) and +45.85% above its 200-day simple moving average ($2.29). Across its 52-week range of $0.92 to $5.96, INDP sits at the 48.0% percentile with a 14-day RSI of 54.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.92 to $3.76).
Why INDP Stock advanced +0.30% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.